Nov 6 (Reuters) - Medical device maker Insulet ( PODD )

on Thursday posted third-quarter results that surpassed Wall

Street's expectations on strong demand for its wearable insulin

pumps, which eliminate the need for daily injections.

Insulet's ( PODD ) sales have risen since the broader approval for

its automated insulin delivery device, Omnipod, that can be

attached to the skin.

Its Omnipod 5 device was cleared in the U.S. for patients

with type 2 diabetes last year, two years after approval for

type 1 diabetes patients.

In September, Insulet ( PODD ) appointed industry veteran Flavia

Pease as the finance chief and said it expects third-quarter

revenue to exceed prior forecasts.

Insulet's ( PODD ) larger peer, Dexcom ( DXCM ), also reported robust demand

for its continuous glucose monitoring systems.

Insulet ( PODD ) now expects annual revenue to grow between 28% and

29% from a year earlier, compared with its previous projection

of 24% to 27%.

The company projects annual Omnipod revenue growth of 29% to

30%, up from a 25% to 28% growth forecast previously.

The devices brought in sales of $699.2 million in the third

quarter, above analysts' estimate of $674.45 million, according

to data compiled by LSEG.

On an adjusted basis, the company earned $1.24 per share for

the quarter, beating estimates of $1.14 apiece.

Total revenue jumped 29.9% to $706.3 million for the quarter

ended September 30, compared with estimates of $676.73 million.